Navigation Links
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET)
Date:7/1/2009

NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  866.272.9941
    International Dial-in Number:  617.213.8895
    Participant Code: 45596036
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 74141589

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                               Media
    Eugenia Shen                            Susan Berg
    BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
    (415) 506-6570                          (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... ... 31, 2016 , ... CURE Media Group , the ... added Cancer and Careers to its Advocacy Spotlight Partnership ... successful careers while fighting cancer. , As partners, both organizations will supply timely ...
(Date:5/30/2016)... Miami, FL (PRWEB) , ... May 30, 2016 , ... ... will means for their children and their efforts to keep their households lice free. ... schools across Hawaii are enacting new policies that keep kids in the classroom despite ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
(Date:5/26/2016)... 26, 2016 Since its commercial ... an essential life science tool for conducting genetic studies ... Research reveals in its new report that the industry ... one powered by a range of new applications in ... (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , Since ...
Breaking Medicine Technology: